A next-generation multitarget stool DNA test, including assessments of DNA molecular markers and hemoglobin level, was developed to improve the performance of colorectal cancer screening, primarily ...

Promising findings by researchers at Baylor College of Medicine and collaborating institutions could lead to the development of a non-invasive stool test and a new therapy for endometriosis, a painful ...

Exact Sciences announced the results of its DeeP-C clinical study comparing the efficacy of Cologuard, a multi-target stool DNA-based screening test, to the fecal immunochemical test. • Cologuard ...

NEW YORK (Reuters Health) - A simplified colorectal cancer screening test that detects tumor DNA in stool is an improvement over an earlier-generation assay, according to North American researchers.

Please provide your email address to receive an email when new articles are posted on . Previously granted FDA breakthrough device designation in January 2020, ColoSense is the “first noninvasive ...

The US Food and Drug Administration (FDA) has approved ColoSense (Geneoscopy, Inc), a multitarget stool RNA (mt-sRNA) test for colorectal cancer (CRC) screening in adults aged 45 or older who are at ...

Colonoscopies are considered the gold standard for detecting colorectal cancer. But some dread the idea of the invasive procedure and the prep required the day before you have it. The FDA last year ...

March marks the beginning of Colorectal Cancer Awareness Month. At-home stool tests can be an easier way to screen for colorectal cancer than a dreaded colonoscopy. As the rates of the cancer continue ...

The Xpert MTB/Ultra molecular diagnostic test for stool samples, until now recommended only for children, could be established as an additional test for diagnosing tuberculosis in adults living with ...